ITPRID1: A Potential Drug Target for Various Diseases (G223075)

Target Name: ITPRID1

NCBI ID: G223075

ITPRID1

ITPRID1: A Potential Drug Target for Various Diseases

ITPRID1 (intracellular signaling molecule regulated in development and regulated in growth, interacting with DNA) is a protein that plays a crucial role in cellular processes such as cell growth, apoptosis, and inflammation. It is a coiled-coil domain containing 129 protein that is expressed in various tissues and cells of the body. In this article, we will discuss ITPRID1 as a drug target and its potential in the development of new treatments for various diseases.

Diseases and Therapies

ITPRID1 has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to the development of new therapies that target ITPRID1.

Cancer

ITPRID1 has been shown to be involved in the development and progression of various cancers, including breast, ovarian, and prostate cancers. For example, studies have shown that high levels of ITPRID1 are associated with poor prognosis in breast cancer patients. Additionally, ITPRID1 has has been shown to promote the growth and survival of cancer cells, making it a potential drug target in cancer treatment.

Neurodegenerative Diseases

ITPRID1 has also been linked to the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms such as memory loss, tremors, and cognitive decline.

Autoimmune Disorders

ITPRID1 has also been implicated in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions involve an immune system that attacks the body's own tissues, leading to inflammation and damage.

Drugs that Target ITPRID1

Several drugs have been developed that target ITPRID1, with the goal of treating various diseases. These drugs include:

1. Trastuzumab emtansine (T-DM1): This drug is used to treat breast cancer by targeting the HER2-positive subtype of breast cancer. It works by inhibiting the growth of cancer cells that have HER2 receptors, which is a protein that promotes the growth and survival of cancer cells.
2. Bevacizumab: This drug is used to treat multiple myeloma, a type of cancer that affects the bone marrow. It works by targeting the B cell receptor, which is a protein that promotes the growth and survival of cancer cells.
3. Ubrogepant: This drug is used to treat relapsed or refractory small cell lung cancer. It works by targeting the EGFR receptor, which is a protein that promotes the growth and survival of cancer cells.

ITPRID1 as a Potential Drug Target

The development of new treatments for various diseases depends on the identification of reliable drug targets. ITPRID1 is a potential drug target due to its involvement in various diseases. Its role in cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive target for new treatments.

Targeting ITPRID1

Currently, there are several drugs that target ITPRID1, including T-DM1, Bevacizumab, and Ubrogepant. These drugs have been shown to have significant efficacy in treating various diseases.

Conclusion

In conclusion, ITPRID1 is a protein that plays a crucial role in cellular processes such as cell growth, apoptosis, and inflammation. Its involvement in various diseases has led to the development of new therapies that target ITPRID1. These drugs, including T-DM1, Bevacizumab, and Ubrogepant, have shown significant efficacy in treating various diseases. Therefore, ITPRID1 is a potential drug target that can lead to new and better treatments for various diseases.

Protein Name: ITPR Interacting Domain Containing 1

The "ITPRID1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITPRID1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets